stocks to buy: Macquarie bullish on Suven Pharma, Divi’s Labs, Bluejet and Syngene

[

Mumbai: Brokerage Macquarie has initiated coverage on Indian contract research, development, and manufacturing (CRDMO) companies catering to global drug makers, and has assigned an ‘Outperform’ ratings to Divi’s Labs, Suven Pharma, Bluejet Healthcare, and Syngene.

Their price targets imply an upside of 19-30% for the shares over the next 12 months.

Macquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressures and geopolitical factors, prompting a global restructuring of the pharmaceutical supply chain.

“We believe favourable geopolitical dynamics, ease of doing business, and strong IP(intellectual property) protection laws further enhance India’s position as a preferred partner for pharmaceutical R&D (research and development) and manufacturing,” said the brokerage’s analysts in a note to their clients.

Macquarie Bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene

The industry has also benefited from the Inflation Reduction Act in the US, which is putting pressure on pharmaceutical companies to cut costs, and the US Biosecure Act, which has not been passed yet but has prompted US-based companies to move from Chinese to Indian and Korean manufacturers.

Macquarie’s analysts said that the higher valuations of Indian companies compared to other peers are justified because they also project higher profitability growth in India.

https://img.etimg.com/thumb/msid-118401241,width-1200,height-630,imgsize-72832,overlay-etmarkets/articleshow.jpg
https://economictimes.indiatimes.com/markets/stocks/news/macquarie-bullish-on-suven-pharma-divis-labs-bluejet-and-syngene/articleshow/118401236.cms

The definitive guide to credential collaboration

Gtech DryOnic hair dryer review: an impressive haircare debut from this vacuum brand

The excellent Bose QuietComfort SC headphones plummet to a record low AU$249

2025 Australian PC Awards winners – all the gear experts reckon is better than the rest

Ex-Israeli Intelligence Official: Shockwaves of Trump’s “Take Over Gaza” Heard, Felt Across Region

What UK political parties are promising in the 2019 general election

Otto Warmbier’s parents want North Korea to suffer for their son’s death

Could a ‘youthquake’ cause Boris Johnson to lose the general election?

Which Celebrity Styles Americans Copy Most in 2025: New Study

New ‘Westworld’ trailer introduces us to another dystopian tech company

What’s the point of ‘Charlie’s Angels’ without Sam Rockwell dancing?

These striking photos capture the future of human flight

Spain's 12-month EU-harmonised inflation unchanged at 2.9% in February

He lost his job because of Donald Trump’s USAID funding freeze. Now he’s helping other laid-off federal workers find work

UniCredit secures ECB's approval for Commerzbank stake

He lost his job because of Donald Trump’s USAID funding freeze. Now he’s helping other laid-off federal workers find work

The YouTuber who has become one of Gen Z’s most beloved celebrities

26 last-minute holiday gifts that are still thoughtful and unique

Practicing gratitude regularly can make you less stressed and sleep better

8 things millennials wish you would just stop getting them for the holidays

stocks to buy: Macquarie bullish on Suven Pharma, Divi’s Labs, Bluejet and Syngene

Spain's 12-month EU-harmonised inflation unchanged at 2.9% in February

He lost his job because of Donald Trump’s USAID funding freeze. Now he’s helping other laid-off federal workers find work

UniCredit secures ECB's approval for Commerzbank stake

He lost his job because of Donald Trump’s USAID funding freeze. Now he’s helping other laid-off federal workers find work

Leave a reply Cancel reply